Oxigene 🔥

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)

Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503

Despite promising science, the company faced periodic financial restructurings, including a significant workforce reduction in 2011 to conserve resources for early-stage programs. Oxigene

The shift to Mateon Therapeutics reflected a broader focus on "Vascular Targeted Therapy" (VTT), which combines VDAs with anti-angiogenic agents to trap and destroy tumor cores while preventing new vessel growth. Historical Acquisitions:

Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye. now MATN). In 2009

On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN).

In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline ZYBRESTAT and OXi4503

Unlike traditional anti-angiogenic drugs that prevent new vessel formation, OXiGENE’s VDAs targeted existing immature blood vessels within tumors. These agents compromise the tumor's core vasculature, leading to extensive necrosis (cell death) within the center of the tumor.